(Q38275128)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

methicillin-resistant Staphylococcus aureus

23 February 2020

main subject

0 references

antibiotic resistance

1 reference

inferred from title

Staphylococcus aureus

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Carmen Lozano

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Carmen Torres

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Fernando Antonanzas

series ordinal

1

1 reference

1 September 2017

publication date

1 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

285-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25447195%20AND%20SRC:MED&resulttype=core&format=json

Clinical, patient experience and cost impacts of performing active surveillance on known methicillin-resistant Staphylococcus aureus positive patients admitted to medical-surgical units

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Staphylococcus aureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-benefit of infection control interventions targeting methicillin-resistant Staphylococcus aureus in hospitals: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality, and costs: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Detection of methicillin-resistant Staphylococcus aureus (MRSA) carrying the mecC gene in wild small mammals in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The emerging problem of linezolid-resistant Staphylococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Community-acquired methicillin-resistant Staphylococcus aureus in Madrid, Spain: transcontinental importation and polyclonal emergence of Panton-Valentine leukocidin-positive isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Detection, molecular characterization, and clonal diversity of methicillin-resistant Staphylococcus aureus CC398 and CC97 in Spanish slaughter pigs of different age groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Empyema caused by MRSA ST398 with atypical resistance profile, Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

High prevalence of spa types associated with the clonal lineage CC398 among tetracycline-resistant methicillin-resistant Staphylococcus aureus strains in a Spanish hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Staphylococcus aureus osteomyelitis in Hawaii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Reference group choice and antibiotic resistance outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Multistate modelling to estimate the excess length of stay associated with meticillin-resistant Staphylococcus aureus colonisation and infection in surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Analysis of MRSA-attributed costs of hospitalized patients in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Healthcare costs associated with hemodialysis catheter-related infections: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Effect of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit on total hospital cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Surgical site infections: Causative pathogens and associated outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Evidence for cost reduction based on pre-admission MRSA screening in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost and effects of different admission screening strategies to control the spread of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost savings of universal decolonization to prevent intensive care unit infection: implications of the REDUCE MRSA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Impact of an antimicrobial-impregnated gauze dressing on surgical site infections including methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals .

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Assessment of the influence of test characteristics on the clinical and cost impacts of methicillin-resistant Staphylococcus aureus screening programs in US hospitals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Chlorhexidine gluconate bathing to reduce methicillin-resistant Staphylococcus aureus acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness of preoperative screening and eradication of Staphylococcus aureus carriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for use with infectio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Predictive value and cost-effectiveness analysis of a rapid polymerase chain reaction for preoperative detection of nasal carriage of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

A cost-saving algorithm for rapid diagnosis of Staphylococcus aureus and susceptibility to oxacillin directly from positive blood culture bottles by combined testing with BinaxNOW® S. aureus and Xpert MRSA/SA Assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Cost avoidance using linezolid for methicillin-resistant Staphylococcus aureus infections in a specialist diabetes foot clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Staphylococcus aureus nasal carriage, virulence traits, antibiotic resistance mechanisms, and genetic lineages in healthy humans in Spain, with detection of CC398 and CC97 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

A Macroeconomic Approach to Evaluating Policies to Contain Antimicrobial Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0242-Y

Medical and health economic evaluation of prevention- and control measures related to MRSA infections or -colonisations at hospitals

21 January 2018

1 reference

12 December 2020

Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?

1 reference

12 December 2020

Cost-benefit and effectiveness analysis of rapid testing for MRSA carriage in a hospital setting

1 reference

12 December 2020

Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis

1 reference

12 December 2020

Clinical update on linezolid in the treatment of Gram-positive bacterial infections

1 reference

12 December 2020

Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals.

1 reference

12 December 2020

Linezolid versus vancomycin for skin and soft tissue infections

1 reference

12 December 2020

Screening cardiac surgery patients for MRSA: an economic computer model.

1 reference

12 December 2020

[Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin]

1 reference

12 December 2020

The costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in Canada

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe.

1 reference

12 December 2020

Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequences

1 reference

12 December 2020

Active surveillance and decolonization of methicillin-resistant Staphylococcus aureus on admission to neonatal intensive care units in Hong Kong: a cost-effectiveness analysis

1 reference

12 December 2020

Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds

1 reference

12 December 2020

Costs of an outbreak of meticillin-resistant Staphylococcus aureus

1 reference

12 December 2020

First outbreak of methicillin-resistant Staphylococcus aureus ST398 in a Dutch hospital, June 2007.

1 reference

12 December 2020

Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment.

1 reference

12 December 2020

[Staphylococcus aureus infection in an acute geriatric unit]

1 reference

12 December 2020

Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin

1 reference

12 December 2020